VANCOUVER, British Columbia,
June 7, 2011 /PRNewswire/ -- Abattis
Biologix Corporation (CNSX: FLU) announced today they have learned
that the U.S. Government has charged Dr. Charles Hensley with unlawfully importing and
distributing an unapproved herbal product named, "Vira 38," in
2005. The federal indictment further charges that Dr. Hensley
unlawfully credited Vira 38 with treating bird flu without FDA
approval.
Recently, Abattis obtained all rights, title and interest to Dr.
Hensley's patent portfolio on the use of an antiviral technology in
humans and poultry. "The efficacy data is compelling and supports
the patent claims made by Dr. Hensley when originally filed,
particularly when the product was compared to the popular influenza
drug Oseltamivir. For example, Dr. Hensley's research
indicated that the compound in Vira 38 outperformed Oseltamivir and
significantly shortened the duration of flu symptoms. Individuals
taking the compounds in the Vira 38 product saw significant
decreases in symptoms within an average of 2.1 days," commented
Mike Withrow, CEO of Abattis.
"Abattis' decision to acquire the intellectual property assets
of Hensley and his partners were based on this efficacy data, which
we believe is sound," said Withrow. "The charges against Dr.
Hensley are based on how he labeled, marketed and imported the
product, and have no bearing on the efficacy or usefulness of the
formulas we acquired if they are properly marketed in the United States," noted Withrow. In
addition, Abbatis is planning to conduct further research to
support the existing efficacy data.
"We firmly believe that our approach of using botanical extracts
with demonstrated anti-bacterial and anti-viral action is an
important effort to bring consumers safe, effective natural
alternatives with meaningful benefits for both human and animal
use," Withrow said.
About Abattis Biologix
Abattis Biologix Corporation is committed to the research,
development and marketing of proprietary, natural health
and wellness solutions that address chronic illnesses
through targeted nutritional
support. We manufacture and market the
most scientifically advanced natural therapeutic
formulas based on proprietary technologies through multiple
distribution channels, while providing the highest level of
customer service.
Media Contact: Margie Adelman
madelman@adelmanpr.com
916 220 3500
SOURCE Abattis Biologix Corporation
